SABCS 2024 | Professor Matteo Lambertini: Optimizing Treatment Strategies for BRCA-Mutated Breast Cancer and Highlights of the SABCS Conference

SABCS 2024 | Professor Matteo Lambertini: Optimizing Treatment Strategies for BRCA-Mutated Breast Cancer and Highlights of the SABCS Conference

2025.02.19
In the field of breast cancer, the treatment of patients with BRCA gene mutations has always been a research hotspot. Recently, at the SABCS conference, Professor Matteo Lambertini from the San Martino Hospital of the University of Genoa, Italy, shared the latest findings on the treatment of BRCA-mutated breast cancer in depth (abstract number: GS1-08). This study aims to explore the impact of risk-reducing surgeries (including prophylactic mastectomy and prophylactic salpingo-oophorectomy) on the survival outcomes of young patients with BRCA-mutated breast cancer. The researchers collected and analyzed data from 5,290 young patients with BRCA-mutated breast cancer from 109 centers worldwide, providing important evidence for the cancer risk management strategies of this specific patient population. Oncology Frontier interviewed Professor Matteo Lambertini on-site at the SABCS conference and invited him to share the highlights of the conference that he focused on.
ASCO GU 2025 | Professor Toni Choueiri on the Future of Casdatifan in Clear Cell Renal Cell Carcinoma

ASCO GU 2025 | Professor Toni Choueiri on the Future of Casdatifan in Clear Cell Renal Cell Carcinoma

2025.02.19
The VHL-HIF pathway is one of the most commonly activated pathways in clear cell renal cell carcinoma (ccRCC). Loss of von Hippel-Lindau (VHL) gene function leads to the stabilization of hypoxia-inducible factors HIF-1α and HIF-2α, driving tumor growth and progression. The development of HIF-2α inhibitors, including belzutifan and casdatifan, has introduced new therapeutic strategies for ccRCC.At the 2025 ASCO GU Annual Meeting, Professor Toni Choueiri from Dana-Farber Cancer Institute presented phase I study results on casdatifan, offering insights into its clinical activity and potential role in renal cell carcinoma treatment.
SOHO 2024 | Dr. Jorge E. Cortes Interprets the ASC4FIRST Study, Aiding in the Optimization of First-line Treatment Options for Newly Diagnosed CML

SOHO 2024 | Dr. Jorge E. Cortes Interprets the ASC4FIRST Study, Aiding in the Optimization of First-line Treatment Options for Newly Diagnosed CML

2025.02.19
The advent of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of chronic myeloid leukemia (CML), transforming its management into a chronic disease model and bringing patient life expectancy close to that of the general population. However, some patients experience treatment failure due to intolerance or insufficient response to at least two existing therapies, or the development of resistance, with consecutive changes in TKIs being associated with an increased risk of treatment failure. Patients with prior treatment intolerance, not achieving major molecular response (MMR) within two years, or with BCR-ABL gene mutations may develop resistance to current TKIs, increasing the risk of disease progression. Moreover, as treatment duration extends, patient demands for treatment tolerability increase. Balancing disease treatment with quality of life is particularly important for long-term survival. During the recent 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024), "Hematology Frontier" had the honor of interviewing Dr. Jorge E. Cortes, Director of the Georgia Cancer Center at the Medical College of Georgia, who discussed the profound impact of Asciminib on current CML treatment patterns and future therapeutic landscapes, based on key findings from the ASC4FIRST study.
SOHO 2024 | Dr. Grzegorz S. Nowakowski Discusses the Latest Advances in First-line Treatment of DLBCL

SOHO 2024 | Dr. Grzegorz S. Nowakowski Discusses the Latest Advances in First-line Treatment of DLBCL

2025.02.19
Diffuse large B-cell lymphoma (DLBCL), as the most common subtype of non-Hodgkin lymphoma, is highly heterogeneous and poses challenges in treatment. Patient prognosis is influenced by various factors, and while the standard R-CHOP regimen is widely used, its efficacy is limited for high-risk groups such as patients with double-hit lymphoma (DHL), necessitating more precise treatment plans. The 12th Annual Meeting of the Society for Hematologic Oncology (SOHO 2024) took place from September 4th to 7th, 2024, in Houston, USA, attracting top experts in the field of hematologic malignancies from around the world to exchange the latest research findings and discuss new strategies for treatment. During the conference, "Hematology Frontier" specially invited Dr. Grzegorz S. Nowakowski from the Mayo Clinic Comprehensive Cancer Center to analyze the latest advances in the treatment of DLBCL and the future direction of treatment strategies, aiming to provide important guidance for clinicians in optimizing treatment plans and making precise therapeutic choices.
World Leukemia Day: Building a Health Defense, Lighting the Flame of Life

World Leukemia Day: Building a Health Defense, Lighting the Flame of Life

2025.02.19
September 4 marks "World Leukemia Day," an initiative launched by the Acute Leukemia Advocates Network, CLL Advocates Network, CML Advocates Network, and Leukaemia Care. The day is dedicated to raising global awareness about leukemia, promoting efforts in prevention, diagnosis, treatment, and recovery. Leukemia, often called "blood cancer," is a complex disease with high treatment costs and the risk of relapse, placing a heavy burden on many families. However, through awareness and action on this day, we aim to break the silence and helplessness, and collectively ignite a beacon of hope for leukemia patients.
Dr. Jin Gu: Significant Benefits of Combined Pelvic Organ Resection for High-Risk Locally Advanced Rectal Cancer | Guangzhou Colorectal Cancer Summit

Dr. Jin Gu: Significant Benefits of Combined Pelvic Organ Resection for High-Risk Locally Advanced Rectal Cancer | Guangzhou Colorectal Cancer Summit

2025.02.19
From August 5th to 10th, 2024, the Guangzhou Colorectal Cancer Summit Forum and the 22nd Guangdong Provincial Colorectal Cancer Academic Conference were held in Guangzhou. During the event, Dr. Jin Gu from Peking University Shougang Hospital shared important insights and conclusions from his center’s experience with combined pelvic organ resection surgery for refractory rectal cancer. After the conference, we had the privilege of interviewing Professor Gu.
CSCO 2024丨Dr. Jiong Wu: INAVO120 Accelerates the Approval of New PI3Ki Inavolisib by CDE, Gene Testing Propels the Era of Precision Targeted Therapy

CSCO 2024丨Dr. Jiong Wu: INAVO120 Accelerates the Approval of New PI3Ki Inavolisib by CDE, Gene Testing Propels the Era of Precision Targeted Therapy

2025.02.19
Hormone receptor-positive (HR+) breast cancer is the most common subtype of breast cancer, with approximately 40% of these patients harboring a PI3KCA mutation. This mutation is a primary cause of resistance to endocrine therapy and CDK4/6 inhibitors, leading to poorer prognosis for affected patients. At the 2024 CSCO Annual Meeting, Dr. Jiong Wu from Fudan University Shanghai Cancer Center, as the Leading PI, shared the latest findings from the Phase III INAVO120 study. The study demonstrated that the novel PI3K inhibitor, inavolisib, combined with CDK4/6 inhibitors and endocrine therapy, offers improved outcomes for these patients, providing a new treatment option. Based on these results, both the China National Medical Products Administration (CDE) and the U.S. FDA have granted fast-track review status to inavolisib, with hopes of delivering clinical benefits to patients soon. At the CSCO meeting, Oncology Frontier had the opportunity to interview Professor Wu, discussing key insights about inavolisib and providing clinical guidance on this emerging PI3K inhibitor.